[go: up one dir, main page]

MX2016010561A - Compuesto heterociclico. - Google Patents

Compuesto heterociclico.

Info

Publication number
MX2016010561A
MX2016010561A MX2016010561A MX2016010561A MX2016010561A MX 2016010561 A MX2016010561 A MX 2016010561A MX 2016010561 A MX2016010561 A MX 2016010561A MX 2016010561 A MX2016010561 A MX 2016010561A MX 2016010561 A MX2016010561 A MX 2016010561A
Authority
MX
Mexico
Prior art keywords
compound
heterocyclic compound
prophylaxis
obesity
medicament
Prior art date
Application number
MX2016010561A
Other languages
English (en)
Inventor
Sasaki Minoru
Kakegawa Keiko
Kikuchi Fumiaki
Ikeda Zenichi
Nishikawa Yoichi
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2016010561A publication Critical patent/MX2016010561A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporciona un compuesto heterocíclico fusionado que tiene una acción inhibidora de la enteropeptidasa, así como el uso del compuesto como medicamento en el tratamiento o la profilaxis de la obesidad, la diabetes mellitus, etc. De forma específica, se proporciona un compuesto representado por la fórmula (I) que aparece a continuación: (ver Fórmula) en donde cada símbolo es como se lo define en la presente, o una sal del mismo, así como el uso del compuesto como medicamento en el tratamiento o la profilaxis de la obesidad, la diabetes mellitus, etc.
MX2016010561A 2014-02-13 2015-02-12 Compuesto heterociclico. MX2016010561A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014025944 2014-02-13
PCT/JP2015/000640 WO2015122188A1 (en) 2014-02-13 2015-02-12 Heterocyclic compound

Publications (1)

Publication Number Publication Date
MX2016010561A true MX2016010561A (es) 2016-11-16

Family

ID=52589730

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010561A MX2016010561A (es) 2014-02-13 2015-02-12 Compuesto heterociclico.

Country Status (22)

Country Link
US (2) US9428470B2 (es)
EP (1) EP3105228B1 (es)
JP (1) JP6458054B2 (es)
KR (1) KR20160113299A (es)
CN (1) CN106170487A (es)
AR (1) AR099399A1 (es)
AU (1) AU2015216439A1 (es)
BR (1) BR112016018548A2 (es)
CA (1) CA2939675A1 (es)
CL (1) CL2016002023A1 (es)
CR (1) CR20160368A (es)
EA (1) EA201691624A1 (es)
EC (1) ECSP16067163A (es)
IL (1) IL247018A0 (es)
MA (1) MA39247B1 (es)
MX (1) MX2016010561A (es)
PE (1) PE20161396A1 (es)
PH (1) PH12016501614A1 (es)
SG (1) SG11201606176YA (es)
TW (1) TW201609677A (es)
UY (1) UY35995A (es)
WO (1) WO2015122188A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2975023B1 (en) 2013-03-13 2018-05-30 Takeda Pharmaceutical Company Limited Guanidinobenzoic acid ester compound
MX386702B (es) 2014-02-10 2025-03-19 Fred Hutchinson Cancer Center Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
PT3105218T (pt) 2014-02-13 2019-12-05 Incyte Corp Ciclopropilaminas como inibidores de lsd1
DK3105226T3 (da) 2014-02-13 2019-10-14 Incyte Corp Cyclopropylaminer som lsd1-inhibitorer
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
JP2018080109A (ja) * 2015-03-16 2018-05-24 武田薬品工業株式会社 治療剤
JP6634070B2 (ja) * 2015-03-27 2020-01-22 武田薬品工業株式会社 縮合複素環化合物
EP3626720A1 (en) 2015-04-03 2020-03-25 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
KR102710120B1 (ko) 2015-08-12 2024-09-27 인사이트 홀딩스 코포레이션 Lsd1 저해제의 염
AU2018361589A1 (en) 2017-11-02 2020-06-04 Ube Corporation Double-headed protease inhibitor
EP3778577B1 (en) * 2018-05-09 2023-08-30 Lg Chem, Ltd. Novel compound exhibiting enteropeptidase inhibitory activity
JP6773938B2 (ja) * 2018-08-27 2020-10-21 株式会社スコヒアファーマ 安息香酸エステル化合物
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
JP7397491B2 (ja) * 2018-10-23 2023-12-13 国立研究開発法人科学技術振興機構 ＰＰＡＲδ活性化剤
US20220281866A1 (en) 2019-07-19 2022-09-08 Janssen Pharmaceutica Nv 5,8-disubstituted-[1,2,4]triazolo[1,5-a]pyridinyl and 5,8-disubstituted-imidazo[1,2-a]pyridine derivatives useful as inhibitors of enteropeptidase
JP7327788B2 (ja) * 2019-08-06 2023-08-16 学校法人福岡大学 糖化産物生成抑制剤及び医薬組成物
JP2023500702A (ja) * 2019-11-04 2023-01-10 ファラデイ ファーマシューティカルズ， インコーポレイテッド 化学療法に関連した悪液質および心毒性の治療ならびに予防のためのヨウ化化合物の使用
WO2021166899A1 (ja) * 2020-02-17 2021-08-26 宇部興産株式会社 インクレチン様物質と組み合わせて使用するための消化管プロテアーゼ阻害剤を含む薬剤
CN111803652B (zh) * 2020-08-04 2021-09-14 南通康是美生物科技有限公司 治疗痤疮的化合物在制备治疗痤疮的药物组合物或化妆品组合物中的用途
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5289640A (en) 1976-01-21 1977-07-27 Ono Pharmaceut Co Ltd Guanidinobenzoic acid derivatives, and antiplasmin agents and remedies for pancreas diseases containing the said guanidinobensolc acid deriv atives
JPS5753454A (en) 1980-09-16 1982-03-30 Torii Yakuhin Kk Guanidinobenzoate and anticomplementary agent
AU527371B2 (en) 1980-09-16 1983-03-03 Torii & Co., Ltd. Amidine
US5116985A (en) 1989-12-28 1992-05-26 Snow Brand Milk Products Co., Ltd. Isoquinoline derivatives and salts thereof
JP2886586B2 (ja) 1989-12-28 1999-04-26 雪印乳業株式会社 新規グアニジノ安息香酸誘導体及びその酸付加塩
JPH0446148A (ja) 1990-06-08 1992-02-17 Asahi Chem Ind Co Ltd ４―グアニジノ安息香酸フェニルエステル誘導体およびそれらを含有する蛋白分解酵素阻害剤
JPH06192085A (ja) 1992-08-31 1994-07-12 Yuji Inada ダニアレルギー治療剤
EP0673924A4 (en) 1992-12-10 1996-04-24 Teikoku Chem Ind Co Ltd PROPRIONIC ACID DERIVATIVE.
JPH0753500A (ja) 1993-08-16 1995-02-28 Sanwa Kagaku Kenkyusho Co Ltd グアニジノ安息香酸誘導体及びこれらを有効成分とする蛋白分解酵素阻害剤
JPH0848664A (ja) 1994-08-05 1996-02-20 Hisamitsu Pharmaceut Co Inc 新規なグアニジノ安息香酸エステル誘導体
EP0862562B1 (en) 1995-09-13 2001-07-04 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
JPH09124571A (ja) 1995-11-01 1997-05-13 Japan Tobacco Inc アミド化合物及びその用途
EP0893437A4 (en) 1996-04-10 2000-12-27 Ono Pharmaceutical Co GUANIDINO TRYPTASE INHIBITOR
JPH10101556A (ja) 1996-09-27 1998-04-21 Ono Pharmaceut Co Ltd ファクターｄ阻害剤
JPH10251239A (ja) 1997-03-14 1998-09-22 Mochida Pharmaceut Co Ltd 新規４ｈ−３，１−ベンゾオキサジン−４−オン誘導体
JPH10306025A (ja) 1997-05-07 1998-11-17 Touin Yokohama Univ 花粉プロテアーゼ阻害剤
AU2001269531A1 (en) 2000-07-17 2002-01-30 Takeda Chemical Industries Ltd. Sulfone derivatives, process for their production and use thereof
ZA200503967B (en) 2002-11-01 2006-11-29 Takeda Pharmaceutical Agent for preventing or treating neuropathy
US7960369B2 (en) 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
CA2507026A1 (en) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited Imidazole derivatives, their production and use
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
WO2005030740A1 (ja) 2003-09-30 2005-04-07 Takeda Pharmaceutical Company Limited チアゾリン誘導体およびその用途
JP4769082B2 (ja) 2003-12-17 2011-09-07 武田薬品工業株式会社 ウレア誘導体、その製造法及び用途
BRPI0418148A (pt) 2003-12-25 2007-04-17 Takeda Pharmaceutical composto, prodroga de um composto, modulador da função do receptor gpr40, agente farmacêutico, uso de um composto e métodos de modificação de uma função do receptor gpr40 em um mamìfero, de profilaxia ou tratamento de diabetes em um mamìfero e de produção de um composto
US7585880B2 (en) 2003-12-26 2009-09-08 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
EP1726580A4 (en) 2004-03-15 2008-02-13 Takeda Pharmaceutical AMINOPHNYLPROPANO ACID DERIVATIVE
US7517910B2 (en) 2004-03-30 2009-04-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US7671057B2 (en) 2004-11-08 2010-03-02 Ono Pharmaceutical Co., Ltd. Therapeutic agent for type II diabetes comprising protease-inhibiting compound
WO2006050999A2 (en) 2004-11-15 2006-05-18 Obe Therapy Biotechnology S.A.S Methods of reducing body fat
ATE401007T1 (de) 2004-11-26 2008-08-15 Nutricia Nv Kleinkindernahrung mit proteasehemmer
CA2605778A1 (en) 2005-04-20 2006-10-26 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US8153694B2 (en) 2005-07-29 2012-04-10 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
US20090054435A1 (en) 2005-07-29 2009-02-26 Hiroshi Imoto Phenoxyalkanoic Acid Compound
PE20070338A1 (es) 2005-08-10 2007-04-16 Takeda Pharmaceutical Derivados heterociclicos como agentes terapeuticos para diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
EP1973405A4 (en) 2006-01-12 2011-06-01 Merck Sharp & Dohme HYDROXYALKYLARYLAMID DERIVATIVES
CA2838448A1 (en) 2006-06-27 2008-01-03 Takeda Pharmaceutical Company Limited Fused cyclic compounds
EP2077267A4 (en) 2006-10-18 2010-04-07 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
CA2666973C (en) 2006-10-19 2015-03-31 Takeda Pharmaceutical Company Limited Indole compound having a glucokinase activating action
US20100016396A1 (en) 2007-01-29 2010-01-21 Hiroshi Imoto Pyrazole compound
KR20090106660A (ko) 2007-02-09 2009-10-09 다케다 야쿠힌 고교 가부시키가이샤 Ｐｐａｒ-감마의 부분 작용제로서의 축합 고리 화합물
WO2008136428A1 (ja) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited 含窒素５員複素環化合物
EP2157859A4 (en) 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
PL2225261T3 (pl) 2007-12-03 2016-09-30 Inhibitory boropeptydowe enteropeptydaz i ich zastosowania w leczeniu otyłości, nadwagi i/lub chorób związanych z nieprawidłowym metabolizmem tłuszczów
EP2511271B1 (en) 2009-12-07 2015-01-21 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
ES2618024T3 (es) 2011-06-07 2017-06-20 Ea Pharma Co., Ltd. Derivado de éster de ácido carboxílico heterocíclico
PL2757093T3 (pl) 2011-09-15 2017-06-30 Astellas Pharma Inc. Związek, kwas guanidynobenzoesowy
ES2644962T3 (es) 2012-01-03 2017-12-01 Oramed Ltd. Cápsulas que contiene composiciones líquidas basadas en aceite de agentes terapéuticos combinados para tratar la diabetes
US9024044B2 (en) 2012-06-14 2015-05-05 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
EP4215205A1 (en) 2013-01-03 2023-07-26 Oramed Ltd. Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof
EA201591614A1 (ru) 2013-03-08 2015-12-30 Эмджен Инк. Соединения 1,3-оксазин-2-амина, конденсированные с перфторированным циклопропилом, в качестве ингибиторов бета-секретазы и способы их применения
EP2975023B1 (en) 2013-03-13 2018-05-30 Takeda Pharmaceutical Company Limited Guanidinobenzoic acid ester compound
SMT202000071T1 (it) 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
ES2784423T3 (es) 2013-09-16 2020-09-25 Astrazeneca Ab Nanopartículas poliméricas terapéuticas y métodos para su fabricación y uso
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
DK3105226T3 (da) 2014-02-13 2019-10-14 Incyte Corp Cyclopropylaminer som lsd1-inhibitorer
PT3105218T (pt) 2014-02-13 2019-12-05 Incyte Corp Ciclopropilaminas como inibidores de lsd1
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound

Also Published As

Publication number Publication date
EP3105228A1 (en) 2016-12-21
IL247018A0 (en) 2016-09-29
US20150225354A1 (en) 2015-08-13
PE20161396A1 (es) 2017-01-10
EP3105228B1 (en) 2018-09-26
CL2016002023A1 (es) 2017-03-24
KR20160113299A (ko) 2016-09-28
BR112016018548A2 (pt) 2019-01-15
AU2015216439A1 (en) 2016-08-11
WO2015122188A1 (en) 2015-08-20
UY35995A (es) 2015-08-31
SG11201606176YA (en) 2016-08-30
CR20160368A (es) 2016-12-01
MA39247A1 (fr) 2017-11-30
PH12016501614A1 (en) 2017-02-06
CN106170487A (zh) 2016-11-30
US20160347724A1 (en) 2016-12-01
TW201609677A (zh) 2016-03-16
US10023544B2 (en) 2018-07-17
JP6458054B2 (ja) 2019-01-23
ECSP16067163A (es) 2017-10-31
EA201691624A1 (ru) 2017-05-31
JP2017505823A (ja) 2017-02-23
CA2939675A1 (en) 2015-08-20
MA39247B1 (fr) 2018-04-30
AR099399A1 (es) 2016-07-20
US9428470B2 (en) 2016-08-30

Similar Documents

Publication Publication Date Title
PH12016501582A1 (en) Fused heterocyclic compound
PH12016501614A1 (en) Heterocyclic compound
TN2016000567A1 (en) Heterocyclic compounds and their use as retinoid-related orphan receptor (ror) gamma-t inhibitors
MX2019010531A (es) Compuesto peptidico.
PH12017550004B1 (en) Heterocyclic derivatives and use thereof
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
TN2017000097A1 (en) Heterocyclic compound
PH12019502248A1 (en) Ip6k inhibitors
MX2015015168A (es) Derivados heterociclicos y sus usos.
MX2016009794A (es) Derivado de sulfonamida heterociclico y medicina que comprende el mismo.
NZ730816A (en) Quinoline carboxamides for use in the treatment of multiple myeloma
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
MY176508A (en) Anti-enterovirus 71 thiadiazolidine derivative
UA90817U (uk) Сполука 1,1-діетилкарбокси-2-трифторметил-2-(5'-бромуридил-1'-)етилен з потенційними фізіологічними властивостями
UA90821U (uk) Сполука 1-1-діетилкарбоксі-2-ізопропокси-2-трифторметилетилен з потенційними фізіологічними властивостями